GlassScriptPhysician profile
Elizabeth Idris
NPI 1255826350
$3,311.02
in general payments reported to CMS, 2019-2025
22 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $434 · 2022: $826 · 2023: $506 · 2024: $1,398 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,235 · Travel and Lodging: $816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.89 |
| Travel and Lodging | $816.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,307.98 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Lilly USA, LLC | $773.67 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $258.29 | 2021-2024 | Ozempic, Wegovy, Rybelsus |
| Sanofi-Aventis U.S. LLC | $162.35 | 2021-2023 | |
| Tandem Diabetes Care, INC. | $136.69 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $93.08 | 2022-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $91.91 | 2022-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.73 | 2022-2023 | |
| Zealand Pharma US, INC. | $59.23 | 2021-2022 | |
| Abbvie INC. | $56.66 | 2021-2022 | |
| Lifescan, INC. | $45.91 | 2021-2023 | |
| Ibsa Pharma INC. | $42.64 | 2022 | |
| Novartis Pharmaceuticals Corporation | $39.02 | 2024-2025 | |
| Esperion Therapeutics, INC. | $32.17 | 2021 | |
| Dexcom, INC. | $24.34 | 2023 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.46 | 2022 | |
| Beta Bionics, INC. | $22.75 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amgen INC. | $18.60 | 2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $17.55 | 2022 | |
| Cequr Corporation | $17.29 | 2025 | Cequr Simplicity |
| Currax Pharmaceuticals LLC | $14.95 | 2023 | Contrave |
| Merck Sharp & Dohme LLC | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Idris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.